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Background: The development of immuno-oncologic agents poses unique challenges, namely that both efficacy
and safety profiles differ from previously characterized cytotoxic and pathway-specific agents. In addition, exponential
distribution is usually assumed in study designs with time-to-event endpoints such as overall survival or
progression-free survival. This assumption might lead to wrong estimates of study duration and statistical power if the
phenomena of long term survival and delayed clinical effects are present. The aim here was to evaluate the
magnitude of the impact caused by the violation of this assumption, and to describe new ways of analyzing efficacy
and safety of immuno-oncologic agents.
Methods: Monte Carlo simulation was implemented to explore the impact of long term survivors and delayed
treatment effect on study power and trial duration. Scenarios with various combinations of long term and delayed
treatment effects were considered. Study power and duration were evaluated based on 10000 randomly generated
trial data sets. The utility of group sequential study designs was discussed. A new set of immune-related response
criteria (irRC) was considered for efficacy analysis. Two new methods for identifying adverse events, termed
immune-related adverse events (irAE) and immune-mediated adverse reactions (imAR) were described. The key
features of the safety profiles derived using these two methods were similar. Both methods were aimed at identifying
inflammatory adverse events caused by immunotherapies.
Results: The presence of long term survivors usually lengthened the study duration. Depending on the treatment
effect post survival curve separation, delayed clinical effect in general led to a loss of power. The irRC offered a new
way of identifying clinical responses. Both safety analyses demonstrated higher sensitivity of identifying adverse
events of immune system origin.
Conclusion: This simulation study showed the importance of accounting for the delayed treatment effect and long
term survivors when these phenomena were expected. Interim analyses for the purpose of stopping the study for
either positive or futile outcome should be implemented with caution in immuno-oncology trials. The new efficacy
analysis offered a potential new way of assessing signs of activity in immunotherapies. While the irAE method
facilitated prompt and effective management of adverse events, the imAR method captured truly immune-related
events.
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Background
Innovative research in recent years has led to the dis-
covery of many promising targeted anti-cancer agents,
including selective or multi-targeted inhibitors of tyrosine
kinases, signal transduction, angiogenesis, or matrix met-
alloproteinase as well as targeted immunotherapies such
as monoclonal antibodies, T cell infusion, and cancer vac-
cines. The varying mechanisms of action introduced by
these novel agents challenge the researchers to reconsider
whether the conventional efficacy and safety analyses as
well as trial designs adequately address these new mecha-
nisms under study.
Cytotoxic and cytostatic agents are classified based on
their mechanism. Classical cytotoxic agents derive their
anti-tumor activity from dose-dependent rapid cell kill.
This mechanism of action, nevertheless, usually results in
undesired toxicities due to the lack of selectivity between
normal and cancerous cells. In contract, cytostatic com-
pounds are agents that suppress cellular growth and
division. These compounds are usually characterized by
minimal or less severe toxicity, prolonged duration of
the treatment, anti-tumor activities at dose levels poten-
tially lower than the maximum tolerated dose (MTD), and
inhibition of tumor growth with absence of or minimum
tumor shrinkage.
Immunotherapies, on the other hand, stimulate the
patient’s own immune system to fight against can-
cers by targeting antigens expressed on cancer cells.
More than any other discovery, monoclonal antibod-
ies (mAbs) have enabled us to identify and manipu-
late molecules regulating the immune system [1]. They
represent a significant subset of immunotherapy agents
being used to treat cancers. One such example is ipil-
imumab, a fully human monoclonal antibody (IgG1)
that blocks cytotoxic T lymphocyte-associated protein
4 (CTLA-4, also known as CD152) to promote immu-
nity. Either alone or in combination with dacarbazine
(DTIC), ipilimumab has demonstrated a statistically sig-
nificant improvement in overall survival (OS) in two phase
III randomized controlled trials in patients with previ-
ously treated and treatment naïve metastatic melanoma
[2,3].
The development process of cytotoxic and cytostatic
agents has been well established. The design of clinical tri-
als progresses from the early phase studies with the goal
of assessing safety to later phase studies evaluating effi-
cacy [4]. Phase I studies aim to assess the side-effects,
the pharmacokinetics of an agent and to determine the
MTD as well as the recommended phase II dose for subse-
quent phase II studies to evaluate the potential anti-tumor
effect. If the agents under investigation are deemed suffi-
ciently efficacious to warrant further investigation, larger
phase III randomized clinical trials are conducted to con-
firm the clinical benefit. This traditional development
paradigm can also be used to assess novel cytostatic agents
and immunotherapies, especially those that may reduce
the total tumor burden. However, with potentially differ-
ent toxicity profiles and different mechanisms that induce
anti-tumor activity, conventional endpoints and/or study
designs may not allow optimal means for evaluating clin-
ical efficacy and safety for these new classes of cancer
therapies.
In this article, the focus will be on the late stage oncology
drug development and the issues introduced by immuno-
oncologic agents. First, several immunotherapies have
been demonstrated to show delayed clinical effect
[2,5-7], in contrast to cytotoxic chemotherapy from which
patients usually derive early benefit. This phenomenon
reduces the statistical power to differentiate between two
treatment arms [8].
In addition, therapies for certain cancer types are
believed to induce a subset of long term survivors, such
as melanoma [2,3,9-12], head and neck cancer [13] and
myeloid leukemia. Since the introduction of imatinib
mesylate and dasatinib, the long term survival (> 5
years) rate of chronic myeloid leukemia patients has been
reported as high as 70% [14,15]. Long term follow-up
demonstrated that treatment with ipilimumab in patients
with treatment-naÃr´ve and previously treated metastatic
melanoma yielded survival rates of 20% beyond four and
five years [16,17]. A long term survival rate in the range of
30% to 50% was also observed in Interferon and pegylated
interferon α-2b in the treatment of adjuvant melanoma.
In this setting, this long-term phenomenon can also
be observed in other time to event endpoints such as
recurrence-free survival (RFS) and distant metastases free
survival (DMFS). Since a subset of the patients in the study
is no longer at risk of progression or death, this implies
that the study duration could be substantially prolonged.
In some occasions, delayed clinical effect and long term
survival were present in the same study. For instance, a
randomized double blind phase III study comparing ipili-
mumab with and without gp100 vaccine vs. gp100 vaccine
alone in patients with pre-treated advanced melanoma
has shown that the Kaplan-Meier survival curves did not
separate until approximately 4 months with a survival
probability leveling off at 20% [2] in the experimental
arms.
Another important aspect of randomized studies is
the use of interim analyses. The implementation of the
group sequential designs has become standard practice in
phase III pivotal studies to allow early study termination
in the face of either positive or negative outcome. Data
have suggested that this standard approach warrants fur-
ther reconsideration with immuno-oncologic products.
For example, a phase III study comparing tremelimumab
to standard-of-care in advanced melanoma was termi-
nated early due to futility as the interim analysis failed to
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demonstrate an overall survival benefit during the follow-
up [18].
The irRC guidelines for evaluating immune response
were developed based on the conventional WHO or
RECIST criteria to capture the unique characteris-
tics exhibited by immuno-oncology agents. Finally, the
conventional safety analysis in the ipilimumab studies
revealed that the adverse event rates were similar between
treatment arms. It was clear that to accurately charac-
terize the safety profile of immuno-oncology agents such
as ipilimumab, it was necessary to develop new methods
to increase the sensitivity and specificity of capturing the
events that were truly of immune system origin.
Here the main goal was to raise the awareness in both
the statistical and clinical communities the importance of
fully understanding the characteristics of the compounds
under investigation, especially immuno-oncologic agents,
in order to determine the optimal trial design and selec-
tion of the best endpoints, as well as the most appropriate
efficacy and safety analysis approaches.
Methods
Long term survival and delayed clinical effect
In a study with time-to-event endpoints, we are interested
in the time interval between the entry of the study and
an event, e.g., the interval between time of randomization
and death or disease progression in a comparative study.
The study is usually designed based on exponential dis-
tribution assumption in which we assume that anything
which affects the hazards does so by the same ratio at all
times, i.e., proportional hazards. This implies the clinical
effect of the experimental arm over the control is observed
from the beginning and the survival curves will eventu-
ally drop down to zero survival probability (Figure 1A).
In general, this assumption is not unreasonable, neverthe-
less, the following two deviations will potentially lead to
an underestimation of study duration or loss of statistical
power.
Due to recent advancement in oncology therapy, a pro-
portion of patients are expected to be cured (or non-
susceptible) in certain diseases, that is to remain alive or
disease-free even after long follow-ups. This phenomenon
is usually observed in Kaplan-Meier curves with non-zero
tail probabilities (Figure 1B, D). Since no one can be really
“cured” of death, the term “cure” refers to one who is not
subject to the event of interest, or who sustains remission
that does not require therapy within any reasonable mon-
itoring time window. This is also known as “functional
cure.”
When the population under study consists of suscepti-
ble and non-susceptible (i.e., functional cured) patients,
the number of patients who are at risk of the event of
interest is smaller. This implies that the time it takes to
reach the required number of events with desired level of
statistical power is lengthened as the events can only be
observed in the subset of susceptible patients.
Another observation that has been made in most ran-
domized immunotherapy trials is the delayed separation
of Kaplan-Meier survival curves (Figure 1C, D). Occasion-
ally the separation may occur months after randomization
[2]. When the delayed separation of survival curves is
present, it violates the fundamental study design assump-
tion of the proportional hazards. The end result is a poten-
tial loss of statistical power to demonstrate the difference
between two treatment arms.
Group sequential procedure
Large randomized clinical trials usually take consider-
able time to enroll patients. In clinical trials involving
human subjects, it is imperative to ensure that indi-
viduals are not exposed to unsafe or ineffective treat-
ments. Due to the life-threatening nature of cancer and
the unmet medical need, it has become common prac-
tice to build in group sequential procedures to assess
the possibility of terminating the studies early for unex-
pected large treatment effects or lack of efficacy that
suggests a positive result at the end of the study would
be extremely unlikely. The former is usually referred to as
the interim analysis for superiority, the latter is that for
futility.
The most popular approaches were group sequential
methods proposed by O’Brien and Fleming [19], Pocock
[20], and error-spending functions by Lan and DeMets
[21] and Pampallona et al. [22]. Both the Pocock and
O’Brien-Fleming procedures require the interim analyses
to be performed at more conservative levels, i.e., smaller
p-values, to avoid excessive false-positive or false-negative
conclusions. The interim analyses are usually specified
based on the information fraction, i.e., the proportion of
total pre-specified number of events. The error-spending
functions are flexible in how many interim analyses are
to be conducted and at what times while maintaining the
overall experiment-wise error rates. They allow review of
unequal increment of the data at unscheduled times.
In an immuno-oncologic randomized clinical trial with
long term survival and delayed clinical effect, one needs
to reconsider the implementation of conventional interim
analyses when the intention is to stop the study early for
either positive or futile outcome. If the treatments exhibit
delayed clinical benefit, implementation of superiority
interim analysis may have smaller stopping probability for
a positive outcome whereas futility interim analysis could
increase the chance of terminating the study early and
erroneously discarding an active agent.
On the other hand, when the treatments under study
yield long term survivors, the outcome of interim anal-
yses can not reflect this unique characteristic of the
treatments since most of the patients are unlikely to
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Figure 1 Graphical presentation of Kaplan-Meier survival curves with various combinations of long term survival and delayed clinical
effect. The following plots show four hypothetical scenarios of overall survival outcome where the red and black curves represent novel
immuno-oncologic agent and a control treatment respectively. (A) Conventional proportional hazards model with exponential assumption; (B)
Proportional hazards model with long term survival; (C) Non-proportional hazards model with delay clinical effect; (D) Non-proportional hazards
cure rate model with long term and delayed effects.
have sufficient follow-ups. Furthermore, the conventional
interim analysis at the information fraction of 50% may
not be the optimal analysis time since the study dura-
tion post interim analysis could take substantially longer
due to the decreasing event rate. Therefore, the tim-
ing of the interim analysis requires careful plannings
such that an interim analysis at a later time may be
desired.
Simulation study
A simulation study was performed in order to evaluate the
impact of long term survival and delayed clinical effect
introduced by immunotherapy as well as the utility of the
interim analysis. A randomized study was first designed
using the conventional exponential distribution assump-
tion, i.e., Proportional Hazards Model (PHM), as a bench-
mark: 512 events were required to detect an overall hazard
ratio of 0.75 between two treatment arms using a log-
rank test with an experiment-wise two-sided type I error
rate of 5% and power of 90%. Furthermore, the accrual
duration for 680 randomized patients was assumed to
be 34 months. The study was expected to attain 512
events approximately 48 months after the first patient was
randomized.
To describe the impact of long term survival and delayed
clinical effect, three survival models were introduced.
First, a Proportional Hazards Cure Rate Model (PHCRM)
added a cured fraction of patients into the proportional
hazards model. Under the same assumptions, the pro-
portional cure rates of 10% vs. 18% were incorporated
between two treatment arms. The proportional cure rates
maintained the risk ratio of the entire population at 0.75
and the power of 90% so the impact on the study dura-
tion could be assessed without inducing the loss of power
simultaneously. If the magnitudes of the proportional cure
rates among non-susceptible patients and the propor-
tional hazards among susceptible patients were different,
the power would be impacted either upwards or down-
wards.
To assess the impact of statistical power under
delayed clinical effect, a Non-Proportional HazardsModel
(NPHM) was used where the first 3 months were assumed
to have hazard ratio of 1 and 0.75 thereafter. This implied
the treatment effect of immunotherapy did not take effect
until month 3.
The last model, a Non-Proportional Hazards Cure Rate
Model (NPHCRM) incorporated both the long term sur-
vival and delayed clinical effect by assuming the hazard
ratio of 1 during the first 3 months and 0.75 post separa-
tion with proportional cure rates of 10% vs. 17%.
Superiority and futility interim analyses with O’Brien-
Fleming procedure at the 50% information fraction were
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also built in for the fourmodels with various combinations
of long term survival and delayed clinical effects to evalu-
ate the efficiency of the interim analysis implementation.
Each scenario was evaluated based on 10000 simu-
lations. The simulated power of each design was the
proportion of iterations that met the criterion of log-rank
test p-value of less than 0.05. The interim stopping proba-
bilities were based on the proportion of iterations among
which the estimated efficacy effect crossed the O’Brien-
Fleming boundaries. The study duration was calculated
based on the median of the simulated durations from
10000 iterations. The median instead of the mean of
simulated study durations was chosen in order to pre-
vent potential outliers from skewing the result, i.e., pre-
specified number of events not reachable.
Results
The simulated statistical powers and study durations
from PHCRM, NPHM and NPHCRM were compared to
those of PHM (Table 1). When a proportion of patients
from both arms were long term survivors (10% vs. 18%),
PHCRM showed that the study duration was extended
from 48 months to 55 months while the power was main-
tained at 90%. If the anticipated treatment effect of hazard
ratio 0.75 was not observed until after the third month,
the pre-specified number of 512 events would only pro-
vide a 70% power, leading to a 20% absolute loss of power
(NPHM). Finally, an immuno-oncologic agent or disease
indication that demonstrated both long term survival and
delayed clinical effect would lead to an under-powered
study, i.e., power of 70%, with extended study duration,
i.e., 54 months, as shown in NPHCRM. Note that the
Table 1 Impact of long term survival and delayed clinical
effect on statistical power and study duration
PHM PHCRM NPHM NPHCRM
Cure rate – 0.10 vs. 0.18 – 0.10 vs. 0.17
Delayed clinical – – 3 3
effect (month)
Sample size 680 680 680 680
Number of events 512 512 512 512
Hazard ratio (pre- and 0.75 0.75 1/0.75 1/0.75
post- separation)
Type I error 0.05 0.05 0.05 0.05
Power 0.90 0.90 0.70 0.70
Accrual duration (month) 34 34 34 34
Study duration (month) 48 55 47 54
A study designed to detect a hazard ratio of 0.75 with two-sided type I error rate
of 5% and power of 90% requires 512 events under exponential assumption. The
study would take 48 months with accrual rate of 20 patients per month for 34
months. When a cured fraction of patients exists in both arms, the study
duration is extended to 55 months. A delayed separation in overall survival
effect would lead to a loss in power. The presence of both long term survival and
delayed clinical effect would lead to an underpowered and lengthy study.
shorter study duration and lower long term survival rate
under NPHCRM compared to those of PHCRM was due
to the first 3 months of delayed clinical effect in the
experimental arm under NPHCRM.
Table 2 illustrated the utility of interim analysis in an
immuno-oncologic trial. An interim analysis at the infor-
mation fraction of 50% was incorporated under the same
design assumption. Based on the same accrual rate of
20 patients per month, the total number of randomized
patients for the four models ranged from 480 to 540 when
256 events were reached. If the treatment were efficacious,
the probability of early termination (PET) in the face of
positive outcome under PHM would be 0.25. However,
this probability reduced to 0.06 when a 3-month delayed
effect was present (NPHM, NPHCRM). Conversely, if a
futility interim analysis were implemented in the design,
the chance of stopping for futile outcome with an effica-
cious treatment would be 0.01 under PHM or PHCRM,
while NPHM or NPHCRM would lead to an increasing
stopping probability of 0.08. With decreasing true posi-
tive rate and increasing false negative rate at the interim
analysis, the necessity and timing of the interim analysis
warrants careful reconsideration.
In addition to the challenges that immuno-modulating
agents created with regards to the study design and
interimmonitoring, two additional issues were being con-
sidered. The first was the choice of response assessment
criteria that accounted for long term benefits of these
agents, and the second was the safety analysis algorithm
that efficiently identified inflammatory adverse events.
Measurement of anti-tumor response: Immune-related
response criteria (irRC)
Anticancer activity derived from chemotherapeutic
agents traditionally has been assessed using modified
World Health Organization (WHO) [23] or Response
Evaluation Criteria in Solid Tumours (RECIST) criteria
Table 2 Interim stopping probability of superiority or
futility with long term survival and delayed clinical effect
PHM PHCRM NPHM NPHCRM
Interim sample size 520 540 480 500
Number of events 256 256 256 256
PETa (superiority) 0.25 0.25 0.06 0.06
PETa (futility) 0.01 0.01 0.08 0.08
Under the same design assumption, we incorporated an interim analysis at the
information fraction of 50%. Based on the same accrual rate of 20 patients per
month, the total number of randomized patients for the four models ranged
from 480 to 540 when 256 events were reached. When a superiority interim
analysis using O’Brien-Fleming boundaries was built into the study design, the
probability of early termination when the agent was active (PETa), i.e., true
positive rate, at the interim analysis under exponential decay was 0.25. The PETa
reduced to 0.06 when the delayed clinical effect of 3 months was present. If a
futility interim analysis was incorporated, the PETa (false negative rate) increased
from 0.01 to 0.08.
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[24,25]. These guidelines standardized the efficacy assess-
ment and facilitated comparison between clinical studies.
However, the underlying operating assumption of these
guidelines lies in the effect of chemotherapeutic agents
on suppressing early tumor growth. Therefore, an appear-
ance of a new lesion signals progressive disease (PD). The
treatment is recommended to be terminated once PD is
detected.
While these guidelines have served us well in evaluat-
ing chemotherapeutic agents, recent research experience
in immuno-oncology has indicated that the clinical ben-
efit from immunotherapy might extend beyond that of
cytotoxic agents. For example, stable disease or responses
to immunotherapy may occur after conventional PD due
to clinically insignificant new lesions in the presence of
other responsive lesions and reduction of the total tumor
burden. Therefore, discontinuation of immunotherapy at
the first sight of PD may not be appropriate in some
cases. In addition, measurable antitumor activity may take
longer for immunotherapies than for cytotoxic agents,
and durable stable disease (SD) may represent meaningful
antitumor activity. A novel set of anti-tumor assessment
criteria, irRC, was therefore proposed based onWHO and
RECIST criteria and has been applied to a series of phase
II and phase III ipilimumab clinical trials [2,3,5,26-28].
The essence of the irRC is the incorporation of the con-
cept of total measurable tumor burden in the assessment
of the anti-tumor activity. Readers can refer to Wolchok
et al. [29] for the detailed description of the irRC guide-
lines. When the irRC is implemented, each patient could
potentially have two progression dates: an earlier date
determined by the conventional criteria and a later one
by the irRC. While the time to event analysis can be
applied to the new irRC by considering the irPD (immune-
related progressive disease) as an event, the depth of the
tumor burden reduction over time can also be studied via
longitudinal data analyses.
One of the biggest challenges of using irRC in assess-
ing immunotherapeutic responses is the uniformity of
implementation among treating physicians. For example,
when treatments are available for patients with PD due
to the appearance of new lesions per conventional mod-
ified WHO or RECIST criteria, treating physicians may
incline to switch the patients to other available therapies
prior to observing delayed benefit rather than prolonging
the time on the current experimental therapies. A large
number of physicians and sites are usually involved in ran-
domized clinical trials. This will render the interpretation
of response assessment results difficult since different cri-
teria were implemented in determining the clinical benefit
within the same study.
Despite the implementation challenge outlined above,
the potential need of a new set of guidelines for immuno-
oncologic agents can not be overlooked. The utility of
irRC will be studied in depth in the near future with richer
data collection when the criteria are more widely adopted.
Measurement of adverse events
Immune-related adverse events (irAE)
Consistent with the idea that immunotherapies fight can-
cer by augmenting the immune response, most adverse
events are expected to be inflammatory in nature. As
such, immunotherapy associated adverse events differed
in character from those observed in melanoma patients
treated with other therapies.
To better identify adverse events likely due to immuno-
oncologic agents such as ipilimumab, a method was devel-
oped to quantify immune-related adverse events (irAEs)
[30]. IrAEs were defined as adverse events of unknown eti-
ology, consistent with an immune phenomenon, consid-
ered by the investigator to be related to treatments. A list
of pre-specified set of Medical Dictionary for Regulatory
Activities (MedDRA) preferred terms of likely immune
system origin was chosen a priori. These terms belong to
six particular system organ classes: Enterocolitis, Hepa-
totoxicity, Dermatitis, Neuropathy, Endocrinopathy, and
Other. The adverse events prospectively identified by the
investigators based on a blinded assessment of individual
events were categorized based on these organ systems in
the irAE analysis.
In contrast to regular safety analyses, the irAEs were
able to better discriminate between adverse events caused
by ipilimumab versus those due to other factors. Never-
theless, adverse events being classified as irAEs continued
to be observed among patients treated with other thera-
pies. The incidence of irAE among these patients should
be closed to zero if the irAE methodology truly captured
only events with immune system origin. A greater speci-
ficity was needed to accurately identify immunotherapy-
specific events and accurately characterize the safety
profile of immuno-oncologic agents such as ipilimumab.
Immune-mediated adverse reactions (imAR)
A new method was developed for the identification of
immune-mediated adverse reactions in order to deter-
mine which adverse events were truly immune-related
[31]. This method was used to retrospectively evaluate
adverse events reported in ipilimumab studies [2,3]. This
methodology differed from irAE method in that: (1) sim-
ilar adverse event records were grouped into contiguous
events; (2) grade 1 events were excluded unless the events
are part of the contiguous events of higher grades, (3)
hepatic laboratory abnormalities, i.e., grade 2+ AST/ALT
elevations, were included in the assessment of hepatic
imAR, and (4) the assessment was performed retrospec-
tively by taking into account the information such as
the use of concomitant medications, and duration of the
adverse events.
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Similar to irAE, the description of the adverse event had
to first include at least one of a set of pre-specified pre-
ferred terms in order for an adverse event to be considered
an imAR. The adverse event records were then reviewed
against a predefined list of criteria for attribution as an
imAR specific to each of the same system organ classes
defined in the previous section (i.e., Enterocolitis, Hepa-
totoxicity, Dermatitis, Neuropathy, Endocrinopathy, and
Other). The determination of imAR was based on the rule
of elimination. If any of the exclusion criteria wasmet, e.g.,
administration of intervening treatment with chemother-
apy proximal to the event known to cause irAE, or rapid
resolution of the adverse event (< 1 week) without initi-
ating concomitant immunosuppressive agents, the event
was adjudicated as not attributed to ipilimumab. Hence,
these adverse events would not be characterized as an
imAR.
For the identification of imARs in ipilimumab [2,3], each
adverse event was adjudicated in a blinded fashion using
the above criteria by two independent physicians. Any
remaining disagreements would trigger a review by a third
physician; the final adjudication was based on a major-
ity vote. The findings from the analyses indicated that the
imAR method yielded great sensitivity and specificity as
the incidence rate of imAR in non-ipilimumab arms fell
close to zero [30,31].
Discussion
Statistical models for time to event analysis typically
assume that everybody in the study population is suscep-
tible to the event of interest and will eventually become
an event. In recent years, due to the innovative medical
advancement, new treatments such as immunotherapies
have yielded long term survivors. Some people in the pop-
ulation may be considered cured or non-susceptible. Fail-
ing to account for these subjects in the study design could
potentially impact the process of drug development and
resource planning. Furthermore, the newly introduced
immuno-oncologic agents may not show early benefit due
to their mechanism of action. This leads to a delayed
separation in Kaplan-Meier curves in time to event
analysis.
In this article, the consequence on statistical power and
study duration in the presence of long term survival and
delayed clinical effects when the study was designed based
on the conventional assumption of exponential distribu-
tion was thoroughly discussed. For illustration purpose,
the clinical trial example provided in this article assumed
a 3-month delayed separation in overall survival curves.
If the separation occurred at a later time, the loss of
power would becomemore severe. Note that the statistical
power was also dependent on the magnitude of the treat-
ment effect post the survival curve separation. If the true
treatment effect post separation exceeds expectations, the
statistical power will improve based on the magnitude of
the treatment effect.
In the simulation study, the proportional cure rates were
assumed in order to evaluate the study duration without
introducing power change. If a PHCM study was designed
and in reality the cure only existed in the experimen-
tal arm, this design would yield an over-powered study.
On the other hand, if the cure existed in the control
arm only, or the magnitude of the proportional cures was
weaker than that of proportional hazards, the study will be
under-powered. Another element that dictates the study
duration is the magnitude of the cure rate. The bigger the
subset of non-susceptible population in a study, the longer
it would take to reach the pre-specified number of events.
Furthermore, the objective of group sequential proce-
dure is to terminate the study in the face of either positive
or futile result prior to the completion of the study. When
the treatment under study possessed the unique immuno-
oncologic characteristics, the necessity of the interim
analyses, for superiority or futility, need to be considered
with caution. If the interim analyses are to be built in,
it is imperative to implement them at the optimal time
points, accounting for clinical, statistical and operational
considerations.
One area that was not touched upon in this article was
the time to event analysis with long term survival and
delayed clinical effect. The most commonly used statis-
tical methods for time to event analyses have been the
log-rank test and Cox regression analysis. These stan-
dard analyses have maximal statistical power under the
proportional hazards assumption. However, they do not
emphasize the treatment effect on the long-term sur-
vivors, which may be of primary interest. In some occa-
sions, researchers may be interested in estimating the
cured fraction. One way of demonstrating long term
survival is to present the survival rates at given time
points, such as one-year or two-year OS rates. If such
analysis is to be conducted, one should ensure the min-
imum follow-up duration is at least as long as the time
point of interest to reduce the number of censored
observations. For example, a minimum follow-up of two
years will yield robust estimates of OS rates up to two
years.
Cure rate models have been a popular topic within sta-
tistical literature, these models can be a useful tool to ana-
lyze and describe time to event data [32-35]. Nevertheless,
the use of such models should be restricted to problems
in which strong biological evidences suggest the presence
of a cured fraction. One important aspect that needs to
consider when speaking of ’cure’ is whether the study pro-
vides sufficient follow-up. The leveling off of the Kaplan–
Meier curve to nonzero proportions, the presence of a
long and stable plateau with a heavy censoring at the tail
may provide evidences of the presence of patients with
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functional cure. A robust estimate of cure fraction can
only be determined with sufficiently long follow-ups [3].
Therefore, one should consider enrolling a smaller num-
ber of patients in an event-driven study to ensure suffi-
cient follow-ups on all patients.
Statistical methodology such as weighted log-rank test
(WLR) [8,36,37] also exists to account for the delayed sep-
aration of Kaplan-Meier curves.When the delayed clinical
effect is present, the WLR test is much more powerful
than the conventional non-parametric log-rank test. Thus,
it is an appropriate alternative to be considered as an
exploratory analysis.
The newly proposed efficacy (irRC) and safety (irAE
and imAR) analyses were also discussed when the treat-
ments under study were immunotherapies. The irRC
modified the widely used WHO or RECIST criteria
by considering the total measurable tumor burden in
the evaluation of anti-tumor activities. The new cri-
teria allow continuation of immunotherapy treatment
in the face of clinically insignificant new lesions in
the presence of responsive lesions, leading to potential
late responses. Ultimately, a proportion of patients who
would have fulfilled conventional criteria for progres-
sive disease was shown to have long term survival rate
similar to that from the conventionally defined respond-
ing patients. The challenge of implementing irRC, sim-
ilar to any assessment guidelines, is to ensure the data
interpretability by applying uniform evaluation across
sites and investigators in clinical trials. The utility of
irRC will be studied in depth in the near future with
richer data collection when the criteria are more widely
adopted.
Two new safety analysis methods were also proposed
to account for the characteristics of immuno-oncologic
therapies. While the prospective irAE method facilitated
prompt and effective management of adverse events,
the retrospective imAR method captured truly immune-
related events. If these new safety analysis methods are
to be implemented, the criteria of irAE/imAR identifi-
cation require careful considerations based on biologi-
cal and clinical evidence for the immunotherapies under
study.
Conclusions
When designing randomized clinical studies with
immunotherapies, the simulation study indicated that
the conventional study design with exponential assump-
tion could lead to an underestimation of either statistical
power or study duration in the presence of delayed clini-
cal effect or long term survival. The necessity and timing
of superiority or futility interim analysis also required
careful consideration due to decreasing true positive rate
or increasing false negative rate. New efficacy and safety
analyses were proposed to account for the mechanism of
action in immunotherapies. These findings have impor-
tant implications for clinical trial researchers aiming to
optimize the drug development process and bring the
novel treatments to cancer patients in need.
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